science

TKM-Ebola

TKM-Ebola is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand TKM-Ebola rather than just read about it. In short: TKM-Ebola was an experimental antiviral drug for Ebola disease that was developed by Arbutus Biopharma (formerly Tekmira Pharmaceuticals Corp.) in Vancouver, Canada. The drug candidate was formerly known as Ebola-SNALP.

Key takeaways

TKM-Ebola belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect TKM-Ebola to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of TKM-Ebola from memory before moving on to harder problems.

Reference excerpt

TKM-Ebola was an experimental antiviral drug for Ebola disease that was developed by Arbutus Biopharma (formerly Tekmira Pharmaceuticals Corp.) in Vancouver, Canada. The drug candidate was formerly known as Ebola-SNALP. TKM-Ebola is a combination of small interfering RNAs targeting three of the seven proteins in Ebola virus: Zaire Ebola L polymerase, Zaire Ebola membrane-associated protein (VP24), and Zaire Ebola polymerase complex protein (VP35). By down-regulating these three proteins, TKM-Ebola inhibits virus replication and eliminates the infection. The drug was effective in rhesus monkeys infected with Ebola. After the Ebola outbreak in West Africa in 2014, the new variant responsible for it was isolated from several Ebola virus families and the specific genomic sequence was determined. The company re-designed TKM-Ebola and renamed it as "TKM-Ebola-Guinea". In January 2014, Tekmira started a Phase I clinical trial of TKM-Ebola to assess its safety in healthy people with a dose of 0.24 mg/kg/day for seven day treatments. The FDA placed the trial on clinical hold in July 2014 to assess results, after some subjects had flu-like responses. In August, the FDA changed the status to "partial hold", allowing the drug to be used under expanded access in people infected with Ebola but with the Phase I trial still suspended. In April 2015 the FDA allowed the study to resume at a lower dose. A Phase II trial started on 11 March 2015 in Sierra Leone, West Africa and stopped enrolling new subjects on 19 June 2015 after it appeared not to work. In July 2015 the company announced it was changing its name to Arbutus, suspending development of the drug for Ebola and changing its focus to developing treatments for hepatitis B virus.

See also Atoltivimab/maftivimab/odesivimab, treatment of Zaire ebolavirus (Ebola virus) Favipiravir ZMapp

References

Worked examples

Example 1 — a first encounter with TKM-Ebola

Start with the simplest possible case. Write down what TKM-Ebola claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to TKM-Ebola before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about TKM-Ebola ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of TKM-Ebola

In research: TKM-Ebola appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses TKM-Ebola in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: TKM-Ebola is common in secondary-school and first-year university syllabi. It links to neighbouring topics Abandoned drugs, Antiviral drugs, Ebola, so understanding it makes those chapters shorter.
In everyday life: Look for TKM-Ebola outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “TKM-Ebola” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study TKM-Ebola in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what TKM-Ebola means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain TKM-Ebola out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is TKM-Ebola in simple terms?

Why does TKM-Ebola matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study TKM-Ebola?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on TKM-Ebola.